FDA Bundling Policy Should Require Full User Fee Payment – MDMA
This article was originally published in The Gray Sheet
Executive Summary
An FDA policy allowing less than full user fee payments for bundled premarket submissions would create a "disadvantage" for small manufacturers, the Medical Device Manufacturers Association states